JP Morgan Chase
ACHL

JP Morgan Chase’s Achilles Therapeutics ACHL Stock Holding History

JP Morgan Chase’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-137
Closed -$156 – 7839
2024
Q4 		$156 Hold
137
– – ﹤0.01% 6948
2024
Q3 		$140 Hold
137
– – ﹤0.01% 6953
2024
Q2 		$112 Hold
137
– – ﹤0.01% 6869
2024
Q1 		$171 Sell
137
-852
-86% -$919 ﹤0.01% 6825
2023
Q4 		$879 Hold
989
– – ﹤0.01% 6852
2023
Q3 		$900 Hold
989
– – ﹤0.01% 6661
2023
Q2 		$935 Hold
989
– – ﹤0.01% 6464
2023
Q1 		$1K Hold
989
– – ﹤0.01% 6566
2022
Q4 		$1K Sell
989
-1,388
-58% -$2.34K ﹤0.01% 6459
2022
Q3 		$5K Buy
2,377
+815
+52% +$2.31K ﹤0.01% 6106
2022
Q2 		$4K Sell
1,562
-3,043
-66% -$7.51K ﹤0.01% 6216
2022
Q1 		$14K Buy
4,605
+1,168
+34% +$4.15K ﹤0.01% 6148
2021
Q4 		$17K Buy
+3,437
New +$20.8K ﹤0.01% 6258
2021
Q3 		– Sell
-49,405
Closed -$484K – 6881
2021
Q2 		$484K Sell
49,405
-576,345
-92% -$7.81M ﹤0.01% 4718
2021
Q1 		$10.4M Buy
+625,750
New +$10.4M ﹤0.01% 2326

Other funds holding ACHL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

JP Morgan Chase's ACHL Position: Q1 2025 in Review

JP Morgan Chase sold out of Achilles Therapeutics (ACHL) in Q1 2025, closing a stake of 137 shares — an estimated $156 sold.

JP Morgan Chase first reported a position in ACHL in Q1 2021 and held it in 15 quarters. The position peaked at $10.4M in Q1 2021. 6 funds tracked by Wall St. Rank hold ACHL as of Q1 2025.

  • JP Morgan Chase reported no remaining Achilles Therapeutics position as of Q1 2025 after selling out during the quarter.
  • JP Morgan Chase sold 137 Achilles Therapeutics shares in Q1 2025, an estimated $156.
  • JP Morgan Chase first reported a position in Achilles Therapeutics in Q1 2021 and held it in 15 quarters.
  • JP Morgan Chase's Achilles Therapeutics position peaked at $10.4M in Q1 2021.
  • 6 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2025.

Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.